A Cambridge company developing new drugs focused around DNA damage and genetically defined cancers has attracted investment from another pharma giant, Pfizer, in its latest funding round, a £20 million Series B.
Pfizer Venture Investments was the only new investor in Mission Therapeutics’ Series B round, which was led by existing investor Sofinnova Partners and also included Imperial Innovations, SR One and Roche Venture Fund, which means it now has three major pharmaceutical companies backing it – SR One is GlaxoSmithKline’s corporate healthcare VC fund.
{iframe}http://www.cabume.co.uk/medtech/pfizer-latest-big-pharma-investor-in-mission-following-p20m-round.html{/iframe}